down arrow

BioSyent, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA0906901081
CAD
11.95
-0.07 (-0.58%)

Dec 17

TSX

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

11.9112.00

52 Week

9.2012.49
Valuation
Technical
Day's Volume

CASH

711

Shareholding (Mar 2025)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Management Efficiency with a high ROE of 18.15%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 7.50

 
3

Positive results in Mar 25

4

With ROE of 21.97%, it has a very attractive valuation with a 3.43 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 136 Million (Small Cap)

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.58

stock-summary
Return on Equity

21.64%

stock-summary
Price to Book

3.41

Revenue and Profits:
Net Sales:
10 Million
(Quarterly Results - Jun 2025)
Net Profit:
2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.42%
0%
-0.42%
6 Months
1.88%
0%
1.88%
1 Year
0.5%
0%
0.5%
2 Years
36.42%
0%
36.42%
3 Years
68.31%
0%
68.31%
4 Years
40.59%
0%
40.59%
5 Years
45.91%
0%
45.91%

BioSyent, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
BioSyent's Valuation Adjustment Highlights Strong Financial Health and Market Position

BioSyent's Valuation Adjustment Highlights Strong Financial Health and Market Position

BioSyent, Inc. has recently experienced a change in its evaluation, reflecting a significant shift in its valuation metrics. The company showcases strong financial health, with competitive ratios and impressive performance indicators, including high returns on capital and equity, alongside robust cash generation capabilities.

Read More
BioSyent Adjusts Valuation Amid Strong Financial Performance and Growth Indicators

BioSyent Adjusts Valuation Amid Strong Financial Performance and Growth Indicators

BioSyent, Inc., a small-cap pharmaceutical company, has recently experienced an evaluation adjustment reflecting its strong financial profile. Key metrics include a 21.97% return on equity, impressive operating cash flow of CAD 8.92 million, and a favorable return on capital employed, highlighting its solid market position and financial health.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
13.72%
EBIT Growth (5y)
12.58%
EBIT to Interest (avg)
7.50
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.96
Tax Ratio
25.74%
Dividend Payout Ratio
29.49%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
100.69%
ROE (avg)
18.15%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
3.43
EV to EBIT
10.78
EV to EBITDA
10.01
EV to Capital Employed
6.25
EV to Sales
2.76
PEG Ratio
0.83
Dividend Yield
NA
ROCE (Latest)
57.94%
ROE (Latest)
21.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -7.27% vs 25.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -13.04% vs 43.75% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10.20",
          "val2": "11.00",
          "chgp": "-7.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.80",
          "val2": "3.20",
          "chgp": "-12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.00",
          "val2": "2.30",
          "chgp": "-13.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "252.10%",
          "val2": "268.60%",
          "chgp": "-1.65%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.76% vs 13.26% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.31% vs 18.18% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.00",
          "val2": "31.60",
          "chgp": "10.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9.20",
          "val2": "8.00",
          "chgp": "15.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7.30",
          "val2": "6.50",
          "chgp": "12.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "246.50%",
          "val2": "238.50%",
          "chgp": "0.80%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
10.20
11.00
-7.27%
Operating Profit (PBDIT) excl Other Income
2.80
3.20
-12.50%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.00
2.30
-13.04%
Operating Profit Margin (Excl OI)
252.10%
268.60%
-1.65%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -7.27% vs 25.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -13.04% vs 43.75% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
35.00
31.60
10.76%
Operating Profit (PBDIT) excl Other Income
9.20
8.00
15.00%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
7.30
6.50
12.31%
Operating Profit Margin (Excl OI)
246.50%
238.50%
0.80%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 10.76% vs 13.26% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 12.31% vs 18.18% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About BioSyent, Inc. stock-summary
stock-summary
BioSyent, Inc.
Pharmaceuticals & Biotechnology
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.
Company Coordinates stock-summary
Company Details
170 Attwell Dr Suite 520 , ETOBICOKE ON : M9W 5Z5
stock-summary
Tel: 1 905 2060013
stock-summary
http://www.biosyent.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."